Description: Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Home Page: www.nutriband.com
121 South Orange Avenue
Orlando,
FL
32801
United States
Phone:
407 377 6695
Officers
| Name | Title |
|---|---|
| Mr. Serguei Melnik | Founder, President, Company Secretary & Executive Chairman of the Board |
| Mr. Gareth Sheridan | Founder, CEO & Director |
| Mr. Gerald Goodman | CFO & Chief Accounting Officer |
| Dr. Alan Smith Ph.D. | COO & President of 4P Therapeutics |
| Dr. Jeffrey Patrick Pharm.D. | Chief Scientific Officer |
| Mr. Michael Myer | President of Pocono Pharmaceutical |
| Mr. Tyler Overk | Head of Active Intelligence |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.9565 |
| Price-to-Sales TTM: | 21.32 |
| IPO Date: | |
| Fiscal Year End: | January |
| Full Time Employees: | 0 |